Table 1.
Baseline Characteristics of PWH Treated With DAAs Between January 2014 and July 2019 (n = 200)
| Median age (range), y | 52 (20–72) |
|---|---|
| Sex, No. (%) | |
| Female | 30 (15) |
| Male | 170 (85) |
| Gender, No. (%) | |
| Cis-gender female | 30 (15) |
| Cis-gender male | 168 (84) |
| Transgender female | 2 (1) |
| Race/ethnicity, No. (%) | |
| White | 153 (76.5) |
| Non-White | 47 (23.5) |
| HIV/HCV risk factor, No. (%) | |
| MSM only | 72 (36) |
| MSM+IDU | 40 (20) |
| IDU only | 78 (39) |
| Heterosexual only | 5 (2.5) |
| Other/unknown | 5 (2.5) |
| HCV genotype, No. (%) | |
| 1/1a | 139 (69.5) |
| 1b | 19 (9.5) |
| 2 | 9 (4.5) |
| 3 | 24 (12) |
| 4 | 8 (4) |
| Other | 1 (0.5) |
| Median CD4 count (range) | 503 (26–2010) |
| HIV VL <50 copies/mL, No. (%) | 184 (92) |
Abbreviations: DAA, direct-acting antiviral; HCV, hepatitis C virus; IDU, intravenous drug use; MSM, men who have sex with men; PWH, people with HIV.